MYMaximus Chun Fai Yeung

Maximus Chun Fai Yeung

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Maximus Chun Fai Yeung has a total of 96 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Uterine NTRK -Rearranged Spindle Cell Neoplasm With Unusual Morphology—A Case Report and Literature Review

    by Horace M.H. Cheung, Maximus C.F. Yeung

    NTRK -rearranged spindle cell neoplasm is a rare lesion in the uterus (including the cervix), with more than 60 tumors reported in the literature so far. Most of them are characterized by fascicles of spindle cells in herringbone pattern with entrapment of endocervical glands. We report an additional tumor occurring in the uterine cervix of a 43-year-old Chinese woman, which demonstrated unusual morphologic features in addition to the conventional fibrosarcoma-like spindle cell proliferation. These included areas of neural-like whorls, as well as nuclear palisading that resembled a schwannoma. Focal myxoid stroma with loose clusters of rhabdoid cells was also identified. The nuclear grade was intermediate to severe and geographic necrosis was identified. Immunohistochemistry showed diffuse positivity for pan-TRK with patchy CD34 and focal S100 expression. Molecular analysis revealed the presence of TPM3::NTRK1 fusion with CDKN2A/B homozygous deletion and low mutational burden. Our case report and literature review highlight the diverse morphological appearance of this tumor. Specifically, nuclear palisading and rhabdoid cells are rarely reported in uterine NTRK -rearranged spindle cell neoplasm. As more clinical and molecular data become available, the clinicopathological features of this entity can be further characterized.

  • SeekFlow: Synergizing Radiology and Pathology Foundation Models for Precision Oncology via Knowledge-Guided Evidence Flow

    by Peixiang Huang, Yanyan Huang, Yihang Chen, Maximus Yeung, Yuming Jiang, Lequan Yu

  • Open Access

    Clinicopathological correlations and immunohistochemical expression of ATRX and Rb in soft tissue leiomyosarcoma: Insights into tumor features and prognostic stratification

    by Maximus C.F. Yeung, Tony W.H. Shek

    Soft tissue leiomyosarcoma (STLMS) remains a challenging malignancy with variable clinical outcomes, highlighting the need for reliable prognostic biomarkers. Recent genomic studies have proposed risk stratification models based on RB1 and ATRX alterations; however, the utility of corresponding immunohistochemical (IHC) surrogates has not been fully explored. In this study, we analyzed clinicopathological features and ATRX/Rb IHC expression in a cohort of 70 STLMS cases to identify correlates of aggressive behavior and assess their prognostic value. Metastasis was significantly associated with female sex ( p = 0.004), age ≤ 60 years ( p = 0.022), internal cavity location ( p = 0.014), necrosis ( p = 0.032), elevated mitotic rate ( p = 0.01), high FNCLCC grade ( p < 0.001), larger tumor size ( p = 0.03), and deep/internal origin. Loss of ATRX staining (44% of cases) correlated significantly with larger tumor size ( p = 0.003), deep location ( p = 0.015), and internal cavity site ( p = 0.007), linking ATRX deficiency to more extensive local disease. Rb loss was frequent (74%) but lacked strong associations with most clinicopathological variables. Although ATRX, Rb, and combined IHC patterns did not significantly stratify overall survival (OS), disease-free survival (DFS), or disease-specific survival (DSS), FNCLCC grade robustly differentiated outcomes, particularly for DFS ( p = 0.000741) and DSS ( p = 0.0206), with a clear trend in OS ( p = 0.0711). Low-grade tumors exhibited no metastases and favorable survival. These findings validate FNCLCC grading as a cornerstone prognostic tool and demonstrate that ATRX IHC identifies clinically relevant subsets with aggressive local features. The observed discordance between IHC and genomic classifiers underscores the complexity of translating molecular alterations to protein-level surrogates, likely due to regulatory mechanisms beyond mutation. This work provides practical insights for risk assessment in STLMS and supports the integration of traditional grading with targeted IHC and molecular profiling for refined patient management.

  • Open Access

    Routine MDM2 FISH Testing and Preoperative Biopsy Reduces Recurrence Rate of Atypical Lipomatous Tumours

    by Samuel O. H. Ching, Anderson S. M. Leung, Raymond C. H. Yau, Albert Y. L. Lam, Tony W. H. Shek, Maximus C. F. Yeung

    Background: Although MDM2 FISH test has been increasingly used to differentiate ALT and benign lipomatous tumours, its impact on clinical outcome remains underexplored. This study investigated whether routine MDM2 FISH testing on preoperative biopsy is associated with a reduction in the recurrence risk of ALT. Methods: A total of 336 patients with MDM2 ‐verified well‐differentiated lipomatous tumours (ALT, n = 67; lipoma, n = 269) treated at a tertiary sarcoma centre were retrospectively analysed. Clinicopathological parameters, histological–molecular concordance, pre‐operative diagnostic approach and recurrence rates were compared. Results: Compared to benign lipomatous tumours, ALT patients were older ( p = 0.002), had larger tumours (median 15.0 vs 7.0 cm, p < 0.001) and more frequently deep extremity lesions ( p < 0.001). Up to 25% of biopsy specimens of ALT exhibit purely benign morphology. ALT patients who underwent preoperative biopsy with MDM2 FISH had a lower recurrence rate than those who did not (16.2% vs 56.7%, p < 0.001). This was associated with a higher rate of extracapsular excision (97.3% vs 71.4%–77.8%, p = 0.021). Conclusion: Routine MDM2 FISH testing on preoperative biopsy provides a definitive diagnosis of ALT, especially for lipoma‐like histology, enabling surgeons to plan extracapsular excision and thereby reducing local recurrence.

  • Open Access

    Integrated Clinicopathologic and Multiomic Profiling Reveals MEIS1-Rearranged Sarcoma as a Distinct Entity With 2 Prognostic Subgroups

    by Maximus C.F. Yeung, Philip P.C. Ip, Jennifer A. Bennett, Jen-Chieh Lee, Mann Hua Nam, Quitterie Fontanges, Basile Tessier-Cloutier, Shuang Niu, Deyin Xing, Gabriela M. Quiroga-Garza, et al.


  • Open Access

    Implementing trust in non-small cell lung cancer diagnosis with a conformalized uncertainty-aware AI framework

    by Xiaoge Zhang, Tao Wang, Chao Yan, Fedaa Najdawi, Kai Zhou, Yuan Ma, Yiu-Ming Cheung, Maximus C. F. Yeung, Bradley A. Malin

    Ensuring trustworthiness is fundamental in cancer diagnostics, where a misdiagnosis can have dire consequences. Current pathology AI models lack systematic solutions to address trustworthiness concerns arising from model limitations and data discrepancies between model deployment and development environments. Here we introduce TRUECAM (Trustworthiness-focused, Uncertainty-aware, End-to-end Cancer diagnosis with Model-agnostic capabilities), a framework designed to ensure both data and model trustworthiness for non-small cell lung cancer subtyping with whole-slide images. TRUECAM integrates (1) a spectral-normalized neural Gaussian process for identifying out-of-scope inputs, (2) an ambiguity-guided tile elimination to filter out highly ambiguous regions, addressing data trustworthiness, and (3) conformal prediction to ensure controlled error rates. We systematically evaluated TRUECAM across multiple cancer datasets using both task-specific and foundation models. Computational experiments suggest that models wrapped with TRUECAM consistently outperformed their unwrapped counterparts in classification accuracy, robustness, interpretability, data efficiency and fairness. These findings establish TRUECAM as a versatile framework for the responsible deployment of pathology AI in real-world settings.


  • Open Access

    Supplementary Figure 2 from Denosumab Enhances Antitumor Immunity by Suppressing SPP1 and Boosting Cytotoxic T Cells

    by Zezhuo Su, Maximus Chun Fai Yeung, Shan Han, Raymond Ching Hing Yau, Ying Lee Lam, Kenneth Wai Yip Ho, Tony Wai Shek, Feng Shi, Shuang Feng, Hongtai Chen, et al.

    Supplementary Figure 2. Comparison of cell-to-cell interaction between neoplastic cells and inflammatory cells in benign GCTB a. Bar charts display the outgoing (top) and incoming (bottom) information flow of neoplastic cells. The "B+" symbol represents denosumab treatment, while the "B-" symbol indicates no denosumab treatment. b. Circle plots demonstrate the cell-to-cell communication signalling network for individual pathways. The size of the vector corresponds to the interaction strength between two cell clusters.

  • Open Access

    Supplementary Figure 6 from Denosumab Enhances Antitumor Immunity by Suppressing SPP1 and Boosting Cytotoxic T Cells

    by Zezhuo Su, Maximus Chun Fai Yeung, Shan Han, Raymond Ching Hing Yau, Ying Lee Lam, Kenneth Wai Yip Ho, Tony Wai Shek, Feng Shi, Shuang Feng, Hongtai Chen, et al.

    Supplementary Figure 6. Pan-cancer analysis of overall survival rates of patients with different levels of CD8A, SPP1, and CD8A:SPP1 a. Overall survival rate of patients stratified by the ration of CD8A:SPP1 estimated using Kaplan–Meier analysis. b. Overall survival rate of patients stratified by the level of CD8A estimated using Kaplan–Meier analysis. c. Overall survival rate of patients stratified by the level of SPP1 estimated using Kaplan–Meier analysis.

  • Open Access

    Supplementary Figure 7 from Denosumab Enhances Antitumor Immunity by Suppressing SPP1 and Boosting Cytotoxic T Cells

    by Zezhuo Su, Maximus Chun Fai Yeung, Shan Han, Raymond Ching Hing Yau, Ying Lee Lam, Kenneth Wai Yip Ho, Tony Wai Shek, Feng Shi, Shuang Feng, Hongtai Chen, et al.

    Supplementary Figure 7. Pan-cancer analysis of SPP1 expression in normal and tumour tissues The y-axis represents the log2 transformed value of the transcripts per million (TPM) incremented by 1. Cancer types with a sample size of fewer than ten individuals per group were excluded from the analysis.

  • Open Access

    Supplementary Figure 5 from Denosumab Enhances Antitumor Immunity by Suppressing SPP1 and Boosting Cytotoxic T Cells

    by Zezhuo Su, Maximus Chun Fai Yeung, Shan Han, Raymond Ching Hing Yau, Ying Lee Lam, Kenneth Wai Yip Ho, Tony Wai Shek, Feng Shi, Shuang Feng, Hongtai Chen, et al.

    Supplementary Figure 5. Comparison of cell-to-cell interaction between benign and malignant GCTB naïve to denosumab treatment a. Bar charts display the outgoing (top) and incoming (bottom) information flow of neoplastic cells. The "M-" symbol represents Malignant, while the "B-" symbol indicates Benign. b. Circle plots demonstrate the cell-to-cell communication signalling network for individual pathways. The size of the vector corresponds to the interaction strength between two cell clusters.